Myriad Genetics Selects Lundbeck as European Partner for Flurizan

SALT LAKE CITY, UT, May 22 / MARKET WIRE/ -- Myriad Genetics, Inc. (NASDAQ: MYGN) (www.myriad.com) today announced the selection of H. Lundbeck A/S for European commercialization of Flurizan?, Myriad's lead therapeutic candidate for the treatment of Alzheimer's disease. Myriad and Lundbeck have... [read full story]                    

Add Comment
There are also 24 related articles
View all news articles about*:
*Newstin tag cloud displays all featured persons, associated organisations, related topics, regions and companies